Long-term carvedilol therapy in patients with stage II arterial hypertension

In total, 30 patients with Stage II arterial hypertension, AH (ESH/ESC 2003; Society of Cardiology of the Russian Federation 2004), mean age 51. 93 ± 7.96years. For 6 months, participants received carvedilol (Talliton, Hungary, Egis) in daily dose 25-75 mg. Microcirculation, hemorheology, and lipid...

Full description

Bibliographic Details
Main Authors: L. I. Markova, A. E. Radzevich
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC  2006-06-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/1841
id doaj-e48086fa95d74d90988f46fe445f7a05
record_format Article
spelling doaj-e48086fa95d74d90988f46fe445f7a052021-07-28T14:02:08Zrus«FIRMA «SILICEA» LLC Российский кардиологический журнал1560-40712618-76202006-06-010363661602Long-term carvedilol therapy in patients with stage II arterial hypertensionL. I. Markova0A. E. Radzevich1Московский государственный медикоFстоматологический университет, кафедра терапии №1 факультета постдипломного образованияМосковский государственный медикоFстоматологический университет, кафедра терапии №1 факультета постдипломного образованияIn total, 30 patients with Stage II arterial hypertension, AH (ESH/ESC 2003; Society of Cardiology of the Russian Federation 2004), mean age 51. 93 ± 7.96years. For 6 months, participants received carvedilol (Talliton, Hungary, Egis) in daily dose 25-75 mg. Microcirculation, hemorheology, and lipid profile were assessed at baseline and after treatment, by conjunctival biomicroscopy and laboratory tests. Carvedilol corrected microcirculation due to its effects on vessels and capillaries, long-term carvedilol treatment didn't affected blood lipid profile, and beneficially influenced hemorheologyhttps://russjcardiol.elpub.ru/jour/article/view/1841carvedilolarterial hypertensionmicrocirculationblood lipid profilehemorheology
collection DOAJ
language Russian
format Article
sources DOAJ
author L. I. Markova
A. E. Radzevich
spellingShingle L. I. Markova
A. E. Radzevich
Long-term carvedilol therapy in patients with stage II arterial hypertension
Российский кардиологический журнал
carvedilol
arterial hypertension
microcirculation
blood lipid profile
hemorheology
author_facet L. I. Markova
A. E. Radzevich
author_sort L. I. Markova
title Long-term carvedilol therapy in patients with stage II arterial hypertension
title_short Long-term carvedilol therapy in patients with stage II arterial hypertension
title_full Long-term carvedilol therapy in patients with stage II arterial hypertension
title_fullStr Long-term carvedilol therapy in patients with stage II arterial hypertension
title_full_unstemmed Long-term carvedilol therapy in patients with stage II arterial hypertension
title_sort long-term carvedilol therapy in patients with stage ii arterial hypertension
publisher «FIRMA «SILICEA» LLC 
series Российский кардиологический журнал
issn 1560-4071
2618-7620
publishDate 2006-06-01
description In total, 30 patients with Stage II arterial hypertension, AH (ESH/ESC 2003; Society of Cardiology of the Russian Federation 2004), mean age 51. 93 ± 7.96years. For 6 months, participants received carvedilol (Talliton, Hungary, Egis) in daily dose 25-75 mg. Microcirculation, hemorheology, and lipid profile were assessed at baseline and after treatment, by conjunctival biomicroscopy and laboratory tests. Carvedilol corrected microcirculation due to its effects on vessels and capillaries, long-term carvedilol treatment didn't affected blood lipid profile, and beneficially influenced hemorheology
topic carvedilol
arterial hypertension
microcirculation
blood lipid profile
hemorheology
url https://russjcardiol.elpub.ru/jour/article/view/1841
work_keys_str_mv AT limarkova longtermcarvediloltherapyinpatientswithstageiiarterialhypertension
AT aeradzevich longtermcarvediloltherapyinpatientswithstageiiarterialhypertension
_version_ 1721269715507085312